Willard Dere

Dr. Dere is Professor Emeritus, University of Utah School of Medicine.  He currently serves on the board of directors for BioMarin, Seres Therapeutics, Mersana Therapeutics and Metagenomi.  Until July 2022, he was Associate Vice President for Research, Co-Director of the Center for Genomic Medicine and Co-Director of the Utah Clinical and Translational Science Institute at the University of Utah Health Sciences. Before joining the University of Utah in 2014, Dr.

Dere was Senior Vice President, Global Development at Amgen, where he led the development of multiple medicines, including denosumab, romiplostim, panitumumab, and cinacalcet. Prior to Amgen, he held various roles at Eli Lilly in the areas of clinical pharmacology, clinical development, and regulatory affairs. Dr. Dere holds a B.A. and M.D. from the University of California, Davis and completed his postdoctoral training at the University of Utah and at the University of California, San Francisco.